… on the basis of the presence of prematurity or chronic lung disease. The purpose of the … and
efficacy of palivizumab in infants and young children with hemodynamically significant CHD. …

… prophylaxis of at-risk children (9,10). Monthly prophylaxis with palivizumab reduced RSV
hospitalizations … (11) and in children aged ≤24 mo with hemodynamically significant CHD (12). …

… , reduces hospitalization from respiratory syncytial virus … , Feltes TF, Piazza FM, Connor
EM and the Cardiac Synagis … with hemodynamically significant congenital heart disease. J …

… trial palivizumab significantly reduced RSV hospitalization in … of 2003, the FDA approved a
label change to include patients with hemodynamically significant congenital heart disease as …

… published in 2003 by the American Academy of Pediatrics.These … Palivizumab prophylaxis
reduces hospitalization due to … of palivizumab for the prevention of respiratory syncytial virus …

… significant congenital cardiac malformations, prophylaxis achieved … Palivizumab prophylaxis
reduces hospitalization due to … Eur J Pediatr 2003; 162: 230–236. 40. American Academy of …

… palivizumab prophylaxis on respiratory syncytial virus (RSV) … of palivizumab for children with
HS-CHD in 2003, the impact … palivizumab in reducing RSV-related hospitalizations among …

… and that its use decreased by 45% the rate of RSV hospitalization… Children with
hemodynamically significant CHD are … requirement of medication for congestive heart failure; and …

… Feltes TF, Cabalka AK, Meissner HC, et al; Cardiac Synagis … with hemodynamically significant
congenital heart disease. … previous 2003 statement (2), the most important modifications …

… viscosity for children with cyanotic heart disease. This trial shows excellent results of
palivizumab in patients with congenital heart disease, including cyanotic heart disease, without any …